These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
465 related articles for article (PubMed ID: 18507275)
1. Racial differences in medication compliance and healthcare utilization among hypertensive Medicaid recipients: fixed-dose vs free-combination treatment. Dickson M; Plauschinat CA Ethn Dis; 2008; 18(2):204-9. PubMed ID: 18507275 [TBL] [Abstract][Full Text] [Related]
2. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Dickson M; Plauschinat CA Am J Cardiovasc Drugs; 2008; 8(1):45-50. PubMed ID: 18303937 [TBL] [Abstract][Full Text] [Related]
3. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Taylor AA; Shoheiber O Congest Heart Fail; 2003; 9(6):324-32. PubMed ID: 14688505 [TBL] [Abstract][Full Text] [Related]
4. Predictors of compliance with antihypertensive therapy in a high-risk medicaid population. Shaya FT; Du D; Gbarayor CM; Frech-Tamas F; Lau H; Weir MR J Natl Med Assoc; 2009 Jan; 101(1):34-9. PubMed ID: 19245070 [TBL] [Abstract][Full Text] [Related]
5. Cost containment for treating hypertension in African Americans: impact of a combined ACE inhibitor-calcium channel blocker. Kountz DS J Natl Med Assoc; 1997 Jul; 89(7):457-60. PubMed ID: 9220694 [TBL] [Abstract][Full Text] [Related]
6. Blood pressure effects of high-dose amlodipine-benazepril combination in Black and White hypertensive patients not controlled on monotherapy. Chrysant SG Drugs R D; 2012 Jun; 12(2):57-64. PubMed ID: 22571394 [TBL] [Abstract][Full Text] [Related]
7. Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. Winer N; Folker A; Murphy JA; Hung E; Bard M; Perkelvald A; Sowers JR; Bakris GL Prev Cardiol; 2005; 8(2):87-92. PubMed ID: 15860983 [TBL] [Abstract][Full Text] [Related]
8. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Gerbino PP; Shoheiber O Am J Health Syst Pharm; 2007 Jun; 64(12):1279-83. PubMed ID: 17563050 [TBL] [Abstract][Full Text] [Related]
9. Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. Sapienza S; Sacco P; Floyd K; DiCesare J; Doan QD Clin Ther; 2003 Jun; 25(6):1872-87. PubMed ID: 12860503 [TBL] [Abstract][Full Text] [Related]
10. Associations between birth weight and antihypertensive medication in black and white medicaid recipients. Lackland DT; Egan BM; Syddall HE; Barker DJ Hypertension; 2002 Jan; 39(1):179-83. PubMed ID: 11799099 [TBL] [Abstract][Full Text] [Related]
11. Racial/ethnic disparities in medication use among veterans with hypertension and dementia: a national cohort study. Poon I; Lal LS; Ford ME; Braun UK Ann Pharmacother; 2009 Feb; 43(2):185-93. PubMed ID: 19193586 [TBL] [Abstract][Full Text] [Related]
12. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy. Baser O; Andrews LM; Wang L; Xie L J Med Econ; 2011; 14(5):576-83. PubMed ID: 21728914 [TBL] [Abstract][Full Text] [Related]
13. Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report. Colvin CL; King JB; Oparil S; Wright JT; Ogedegbe G; Mohanty A; Hardy ST; Huang L; Hess R; Muntner P; Bress A JAMA Netw Open; 2020 Nov; 3(11):e2025127. PubMed ID: 33206191 [TBL] [Abstract][Full Text] [Related]
14. [Comparison of benazepril monotherapy to amlodipine plus benazepril in the treatment of patients with mild and moderate hypertension: a multicentre, randomized, double-blind, parallel-controlled study]. Fan CM; Yan LR; Tao YK; Wang L; Li YQ; Gao MM; Wang YN; Li CX; Wang XW; Lu XL; Pang HM; Li YS Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jan; 39(1):57-60. PubMed ID: 21418799 [TBL] [Abstract][Full Text] [Related]
15. Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy. Perrone V; Veronesi C; Gambera M; Nati G; Perone F; Tagliabue PF; Degli Esposti L; Volpe M High Blood Press Cardiovasc Prev; 2019 Oct; 26(5):399-404. PubMed ID: 31463886 [TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan. Tung YC; Lin YS; Wu LS; Chang CJ; Chu PH J Clin Hypertens (Greenwich); 2015 Jan; 17(1):51-8. PubMed ID: 25477188 [TBL] [Abstract][Full Text] [Related]
17. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension. Hilleman DE; Reyes AP; Wurdeman RL; Faulkner M J Hum Hypertens; 2001 Aug; 15(8):559-65. PubMed ID: 11494095 [TBL] [Abstract][Full Text] [Related]
19. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. Jamerson K; Weber MA; Bakris GL; Dahlöf B; Pitt B; Shi V; Hester A; Gupte J; Gatlin M; Velazquez EJ; N Engl J Med; 2008 Dec; 359(23):2417-28. PubMed ID: 19052124 [TBL] [Abstract][Full Text] [Related]
20. Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis. Shenolikar RA; Balkrishnan R; Camacho FT; Whitmire JT; Anderson RT Clin Ther; 2006 Aug; 28(8):1199-1207. PubMed ID: 16982297 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]